Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...

Eli Lilly is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using ...

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...

Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

In this article, we will take a look into Eli Lilly and Co's (NYSE:LLY) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow as ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses ...

New 7.5 mg and 10 mg Zepbound single-dose vials now available for $499 per month via Zepbound Self Pay Journey Program 2.5 mg and 5 mg vial prices reduced INDIANAPOLIS ...